Nesfatin-1 ameliorates blood-brain barrier dysfunction in Alzheimer’s disease by targeting VEGF-R1 and reducing cellular senescence in brain vascular endothelial cells
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-09-03 22:26
摘要：
Nesfatin-1 (NF-1) has been shown to improve blood-brain barrier (BBB) dysfunction in Alzheimer's disease (AD) by targeting VEGF-R1 and reducing cellular senescence in brain endothelial cells. The study found that NF-1 treatment restored the expression of tight junction proteins and mitigated the permeability increase induced by oligomerized Aβ1-42. In transgenic AD mouse models, NF-1 administration decreased VEGF-R1 levels, suggesting a protective role for NF-1 in maintaining BBB integrity and offering a potential therapeutic avenue for AD.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
0.5分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
0.5分
关键证据
NF-1 treatment improved cellular senescence in brain vascular endothelial cells.
NF-1 reduced oligomerized Aβ1-42-induced endothelial monolayer permeability.
NF-1 administration lowered VEGF-R1 expression in the brain cortex of AD mice.
真实性检查
否
AI评分总结
Nesfatin-1 (NF-1) has been shown to improve blood-brain barrier (BBB) dysfunction in Alzheimer's disease (AD) by targeting VEGF-R1 and reducing cellular senescence in brain endothelial cells. The study found that NF-1 treatment restored the expression of tight junction proteins and mitigated the permeability increase induced by oligomerized Aβ1-42. In transgenic AD mouse models, NF-1 administration decreased VEGF-R1 levels, suggesting a protective role for NF-1 in maintaining BBB integrity and offering a potential therapeutic avenue for AD.